Teglarinad chloride (GMX1777) is a prodrug of GMX1778, a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, exhibiting antitumor activity in mice through NAMPT inhibition; it enhances radiotherapy efficacy by interfering with DNA repair and exerting anti-angiogenic effects; it induces tumor regression in multiple xenograft models including IM-9 multiple myeloma, small-cell lung cancer (SHP-77), and colon carcinoma (HCT-116); it demonstrates significant antitumor activity against FaDu and C666-1 tumors in vivo, both as a monotherapy and in combination with local tumor radiotherapy.